[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AP2002002698A0 - 3-Azabicyclo[3.1.0] hexane derivatives useful in therapy. - Google Patents

3-Azabicyclo[3.1.0] hexane derivatives useful in therapy.

Info

Publication number
AP2002002698A0
AP2002002698A0 APAP/P/2002/002698A AP2002002698A AP2002002698A0 AP 2002002698 A0 AP2002002698 A0 AP 2002002698A0 AP 2002002698 A AP2002002698 A AP 2002002698A AP 2002002698 A0 AP2002002698 A0 AP 2002002698A0
Authority
AP
ARIPO
Prior art keywords
opiate
useful
pharmaceutically
azabicyclo
therapy
Prior art date
Application number
APAP/P/2002/002698A
Inventor
Bernard Joseph Banks
Douglas James Critcher
Ashley Edward Fenwick
David Morris Gethin
Paul Stephen Gibson
Graham Lunn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2002002698A0 publication Critical patent/AP2002002698A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of formula (1), where the substituents are as defined herein, and the pharmaceutically or veterinarily acceptable derivatives or prodrugs thereof, are pharmaceutically and veterinarily useful, in particular they bind to opiate receptors, (e.g. mu, kappa and delta opioid receptors). They are likely to be useful in the treatment of diseases or conditions modulated by opiate receptors, for example irritable bowel syndrome; constipation; nausea; vomiting; pruritic dermatoses, such as allergic dermatitis and atopy; eating disorders; opiate overdoses; depression; smoking and alcohol addiction; sexual dysfunction; shock; stroke; spinal damage; and head trauma.
APAP/P/2002/002698A 2000-06-23 2001-06-07 3-Azabicyclo[3.1.0] hexane derivatives useful in therapy. AP2002002698A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015562.2A GB0015562D0 (en) 2000-06-23 2000-06-23 Heterocycles
PCT/IB2001/001035 WO2001098267A1 (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity

Publications (1)

Publication Number Publication Date
AP2002002698A0 true AP2002002698A0 (en) 2002-12-31

Family

ID=9894368

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002698A AP2002002698A0 (en) 2000-06-23 2001-06-07 3-Azabicyclo[3.1.0] hexane derivatives useful in therapy.

Country Status (34)

Country Link
EP (1) EP1292574A1 (en)
JP (1) JP2004512263A (en)
KR (1) KR20040002386A (en)
CN (1) CN1639121A (en)
AP (1) AP2002002698A0 (en)
AR (1) AR028969A1 (en)
AU (1) AU781837B2 (en)
BG (1) BG107329A (en)
BR (1) BR0111867A (en)
CA (1) CA2412188A1 (en)
CZ (1) CZ20023967A3 (en)
DO (1) DOP2001000187A (en)
DZ (1) DZ3368A1 (en)
EA (1) EA005117B1 (en)
GB (1) GB0015562D0 (en)
HR (1) HRP20020998A2 (en)
HU (1) HUP0301228A3 (en)
IL (1) IL153427A0 (en)
IS (1) IS6637A (en)
MA (1) MA26915A1 (en)
MX (1) MXPA02012878A (en)
NO (1) NO20026168L (en)
NZ (1) NZ523141A (en)
OA (1) OA12293A (en)
PA (1) PA8519401A1 (en)
PE (1) PE20020253A1 (en)
PL (1) PL365956A1 (en)
SK (1) SK17172002A3 (en)
TN (1) TNSN01094A1 (en)
UA (1) UA73176C2 (en)
UY (1) UY26787A1 (en)
WO (1) WO2001098267A1 (en)
YU (1) YU91802A (en)
ZA (1) ZA200210278B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1440059T1 (en) 2001-10-22 2008-08-31 Pfizer Prod Inc 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
PL371596A1 (en) * 2002-05-17 2005-06-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
DE10259245A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivatives of asimadolin with covalently bound acids
ATE542816T1 (en) * 2004-02-23 2012-02-15 Glaxo Group Ltd AZABICYCLOÄ3.1.0HEXANE DERIVATIVES AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
DE602007012531D1 (en) * 2006-04-03 2011-03-31 Glaxo Group Ltd AZABICYCLOA3.1.0 OXIDE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
KR101208326B1 (en) 2007-03-30 2012-12-05 티오가 파마슈티칼스, 인코포레이티드 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
TWI423801B (en) * 2007-08-27 2014-01-21 Theravance Inc 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
CA2936749C (en) 2010-06-11 2019-07-09 Joshua R. Giguere Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
WO2012042539A2 (en) 2010-09-28 2012-04-05 Panacea Biotec Ltd Novel bicyclic compounds
CN105764888B (en) * 2013-11-20 2018-04-06 株式会社三和化学研究所 A kind of new 3 azabicyclos [3.1.0] hexame derivatives and its medical usage
MX2017014835A (en) 2015-05-20 2018-02-19 Sanwa Kagaku Kenkyusho Co Crystal of salt of novel 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof.
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN110520129A (en) * 2017-02-17 2019-11-29 特维娜有限公司 Delta opiate receptor modulating compound and its use and preparation method containing 5 yuan of aza heterocycles
JPWO2018159716A1 (en) 2017-03-02 2019-12-26 株式会社三和化学研究所 Drugs for alcohol use disorders
CN108250088B (en) * 2018-01-04 2020-10-30 四川之江高新材料股份有限公司 Preparation method of N, N, N '-trimethyl-N' -hydroxyethyl bisaminoethylether
CN115825305B (en) * 2022-10-21 2024-09-20 昆明理工大学 Molecularly imprinted solid-phase microextraction fiber and preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
AR245933A1 (en) * 1987-04-16 1994-03-30 Lilly Co Eli Piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
DE4341403A1 (en) * 1993-12-04 1995-06-08 Basf Ag N-substituted 3-azabicycloalkane derivatives, their preparation and use
PE20001420A1 (en) * 1998-12-23 2000-12-18 Pfizer CCR5 MODULATORS
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Also Published As

Publication number Publication date
HUP0301228A2 (en) 2003-08-28
PE20020253A1 (en) 2002-04-08
CZ20023967A3 (en) 2004-02-18
HRP20020998A2 (en) 2004-02-29
EA005117B1 (en) 2004-10-28
OA12293A (en) 2004-03-18
BG107329A (en) 2003-07-31
CN1639121A (en) 2005-07-13
AU781837B2 (en) 2005-06-16
AR028969A1 (en) 2003-05-28
UY26787A1 (en) 2002-01-31
ZA200210278B (en) 2003-12-19
PA8519401A1 (en) 2002-12-30
JP2004512263A (en) 2004-04-22
MXPA02012878A (en) 2003-05-14
PL365956A1 (en) 2005-01-24
IL153427A0 (en) 2003-07-06
CA2412188A1 (en) 2001-12-27
AU6259101A (en) 2002-01-02
YU91802A (en) 2006-05-25
WO2001098267A8 (en) 2003-02-27
DOP2001000187A (en) 2002-03-30
NZ523141A (en) 2005-06-24
HUP0301228A3 (en) 2005-08-29
WO2001098267A1 (en) 2001-12-27
EA200201269A1 (en) 2003-06-26
IS6637A (en) 2002-11-28
BR0111867A (en) 2003-07-01
MA26915A1 (en) 2004-12-20
TNSN01094A1 (en) 2005-11-10
NO20026168L (en) 2003-02-18
SK17172002A3 (en) 2004-09-08
EP1292574A1 (en) 2003-03-19
GB0015562D0 (en) 2000-08-16
DZ3368A1 (en) 2001-12-27
UA73176C2 (en) 2005-06-15
NO20026168D0 (en) 2002-12-20
KR20040002386A (en) 2004-01-07

Similar Documents

Publication Publication Date Title
AP2002002698A0 (en) 3-Azabicyclo[3.1.0] hexane derivatives useful in therapy.
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
TW200503713A (en) Novel compounds
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
MX337817B (en) PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES.
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
UA84930C2 (en) Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
WO2009066775A1 (en) Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2003013435A3 (en) N-acetyl-d-glucosamine and process for producing n-acetyl-d-glucosamine
IL188184A0 (en) Pyrazolo [3,4-d] azepine derivatives as histamine h3 antagonists
TW200514781A (en) Novel compounds
WO2009125923A3 (en) Novel indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient
DE602004024188D1 (en) THE OPIOID RECEPTOR
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2007107276A3 (en) Process for preparing c7 intermediates and their use in the preparation of n-substituted pyrrole derivatives
WO2007127421A3 (en) Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes
WO2004089908A3 (en) 3-azabicyclo[3.2.1]octane derivatives
MX2007006754A (en) Indenyl derivatives and use thereof for the treatment of neurological disorders.